Neuroendocrine neoplasia goes molecular — time for a change

Guido Rindi; Bertram Wiedenmann

doi:10.1038/s41571-018-0118-8

Neuroendocrine neoplasia goes molecular — time for a change

Guido Rindi
, Bertram Wiedenmann

Charité – Universitätsmedizin Berlin

Risultato della ricerca: Contributo in rivista › Articolo

7 Citazioni (Scopus)

Abstract

In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

Lingua originale	Inglese
pagine (da-a)	149-150
Numero di pagine	2
Rivista	NATURE REVIEWS. CLINICAL ONCOLOGY
Volume	16
DOI	https://doi.org/10.1038/s41571-018-0118-8
Stato di pubblicazione	Pubblicato - 2019

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

NEN

Accesso al documento

10.1038/s41571-018-0118-8

Altri file e collegamenti

Cita questo

@article{fafc6c994a5d453ea39600eb5b26b0cc,

title = "Neuroendocrine neoplasia goes molecular — time for a change",

abstract = "In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.",

keywords = "NEN, NEN",

author = "Guido Rindi and Bertram Wiedenmann",

year = "2019",

doi = "10.1038/s41571-018-0118-8",

language = "English",

volume = "16",

pages = "149--150",

journal = "NATURE REVIEWS. CLINICAL ONCOLOGY",

issn = "1759-4774",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Neuroendocrine neoplasia goes molecular — time for a change

AU - Rindi, Guido

AU - Wiedenmann, Bertram

PY - 2019

Y1 - 2019

N2 - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

AB - In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

KW - NEN

UR - http://hdl.handle.net/10807/133445

UR - http://www.nature.com/nrclinonc/archive/index.html

U2 - 10.1038/s41571-018-0118-8

DO - 10.1038/s41571-018-0118-8

M3 - Article

SN - 1759-4774

VL - 16

SP - 149

EP - 150

JO - NATURE REVIEWS. CLINICAL ONCOLOGY

JF - NATURE REVIEWS. CLINICAL ONCOLOGY

ER -

Neuroendocrine neoplasia goes molecular — time for a change

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo